


Product Name	: Evacetrapib
Synonyms	: LY2484595; LY 2484595; LY-2484595
Cat No.	: M10636
CAS Number	: 1186486-62-3
Molecular Formula	: C ₃₁ H ₃₆ F ₆ N ₆ O ₂
Formula Weight	: 638.70
Chemical Name	: Cyclohexanecarboxylic acid, 4-[[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-, trans-
Description	Evacetrapib (LY2484595) is a potent and selective inhibitor of cholesteryl ester transfer protein (CETP) with IC₅₀ of 5.5 nM for human recombinant CETP protein; inhibits CETP activity in human plasma with IC₅₀ of 36 nM; shows no significant inhibition in the CEREP cell surface receptor screening, as well as the nuclear receptor panel; exhibits an ex vivo CETP inhibition ED₅₀ of < 5 mg/kg at 8 h post oral dose and significantly elevates HDL cholesterol in vivo; Evacetrapib is a potent and selective CETP inhibitor without torcetrapib-like off-target liabilities. Dyslipidemia Discontinued
Pathway	: Metabolic Enzyme/Protease
Target	: CETP
Receptor	: CETP
Solubility	: 10 mM in DMSO
SMILES	: <chem>O=C([C@H]1CC[C@H](CN2C3=C(C)C=C(C)C=C3[C@@H](N(CC4=CC(C(F)(F)F)=CC(C(F)(F)F)=C4)C5=NN(C)N=N5)CCC2)CC1)O</chem>
Storage	: (-20°C)
Stability	: ≥ 2 years
Reference	:



1. Cao G, et al. J Lipid Res. 2011 Dec;52(12):2169-76.
2. Nicholls SJ, et al. JAMA. 2011 Nov 16;306(19):2099-109.
3. Barter PJ, et al. J Lipid Res. 2012 Sep;53(9):1755-66.
4. Suico JG, et al. J Cardiovasc Pharmacol Ther. 2014 May;19(3):283-9.